Incidence of febrile neutropenia in early stage breast cancer patients receiving adjuvant FEC-D treatment.
about
Adjuvant taxane-based chemotherapy for early stage breast cancer: a real-world comparison of chemotherapy regimens in Ontario.The risk of febrile neutropenia in breast cancer patients following adjuvant chemotherapy is predicted by the time course of interleukin-6 and C-reactive protein by modelling.
P2860
Incidence of febrile neutropenia in early stage breast cancer patients receiving adjuvant FEC-D treatment.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Incidence of febrile neutropen ...... ving adjuvant FEC-D treatment.
@en
type
label
Incidence of febrile neutropen ...... ving adjuvant FEC-D treatment.
@en
prefLabel
Incidence of febrile neutropen ...... ving adjuvant FEC-D treatment.
@en
P2093
P2860
P1476
Incidence of febrile neutropen ...... ving adjuvant FEC-D treatment.
@en
P2093
Daniel Rayson
Hazem Assi
Joshua Murray
Laura Boyle
P2860
P2888
P304
P356
10.1007/S00520-014-2318-9
P577
2014-07-05T00:00:00Z